Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers

British Journal of Clinical Pharmacology

Volumn 46, Issue 2, 1998, Pages 111-116

  Ouellet, Daniele ^a,b   Hsu, Ann ^a   Qian, Jiang ^a   Locke, Charles S ^a   Eason, Carolyn J ^a   Cavanaugh, John H ^a   Leonard, John M ^a   Granneman, G Richard ^a  

^a ABBOTT LABORATORIES   (United States)

^b MDS Inc   (Canada)

Author keywords

Drug interaction; Ethinyl oestradiol; Glucuronidation; Induction; Oral contraceptive; Pharmacokinetics; Protease inhibitor; Ritonavir

Indexed keywords

CYTOCHROME P450; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS ETYNODIOL DIACETATE; ORAL CONTRACEPTIVE AGENT; PROTEINASE INHIBITOR; RITONAVIR;

ADULT; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG GLUCURONIDATION; DRUG HALF LIFE; DRUG HYDROXYLATION; FEMALE; GAS CHROMATOGRAPHY; HEADACHE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; HYPESTHESIA; NAUSEA; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PARESTHESIA; PRIORITY JOURNAL; STATISTICAL ANALYSIS; VASODILATATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME--PREVENTION AND CONTROL; AMERICAS; CLINICAL RESEARCH; CONTRACEPTION; CONTRACEPTIVE AGENTS, ESTROGEN--PHARMACODYNAMICS; CONTRACEPTIVE AGENTS, FEMALE--PHARMACODYNAMICS; CONTRACEPTIVE AGENTS--PHARMACODYNAMICS; CONTRACEPTIVE METHODS; DEVELOPED COUNTRIES; DISEASES; DRUG INTERACTIONS; DRUGS; ETHINYL ESTRADIOL--PHARMACODYNAMICS; FAMILY PLANNING; HIV INFECTIONS--PREVENTION AND CONTROL; NORTH AMERICA; NORTHERN AMERICA; ORAL CONTRACEPTIVES; ORAL CONTRACEPTIVES, COMBINED; RESEARCH METHODOLOGY; RESEARCH REPORT; TREATMENT; UNITED STATES; VIRAL DISEASES;

ADULT; ANTI-HIV AGENTS; AREA UNDER CURVE; CONTRACEPTIVES, ORAL; DRUG INTERACTIONS; ESTRADIOL CONGENERS; ETHINYL ESTRADIOL; FEMALE; HALF-LIFE; HIV PROTEASE INHIBITORS; HUMANS; MIDDLE AGED; RITONAVIR;

EID: 0031857385     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1998.00749.x     Document Type: Article

References (29)

1. Robins T, Plattner J. HIV protease inhibitors: their anti-HIV activity and potential role in treatment. J Acquir Immune Defic Syndr 1993; 6: 162-170.
2. Kempf DJ, Marsh KC, Denissen JF, et al. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc Natl Acad Sci 1995; 92: 2484-2488.
3. Danner SA, Carr A, Leonard JM, et al. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. N Engl J Med 1995; 333: 1528-1533.
4. Markowitz M, Saag M, Powderly WG, et al. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med 1995; 333: 1534-1539.
5. Kumar GN, Rodrigues AD, Buko AM, Denissen JF. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J Pharmacol Exp Ther 1996; 277: 423-431.
6. Orme ML, 'E, Back DJ, Breckenridge AM. Clinical pharmacokinetics of contraceptive steroids. Clin Pharmacokin 1983; 8: 95-136.
7. Newburger J, Goldzieher JW. Pharmacokinetics of ethinyl estradiol: A current view. Contraception 1985; 32: 33-44.
8. Shenfield GM, Griffin JM. Clinical pharmacokinetics of contraceptive steroids - An update. Clin Pharmacokin 1991; 20: 15-37.
9. Guengerich FP. Minireview: Metabolism of 17α-ethinylestradiol in humans. Life Sci 1990; 47: 1981-1988.
10. Orme ML, 'E, Back DJ, Ball S. Pharmacokinetic drug interactions with oral contraceptives. Clin Pharmacokin 1990; 18: 472-484.
11. Jung-Hoffman C, Kuhl H. Pharmacokinetics and pharmacodynamics of oral contraceptive steroids: Factors influencing steroid metabolism. Am J Obstet Gynecol 1990; 163: 2183-2197.
12. Marsh KC, Eiden E, McDonald E. Determination of ritonavir, a new HIV protease inhibitor, in biological samples using reversed-phase high-performance liquid chromatography with electrochemical detection. J Chromatogr B in press.
13. Fieller E. Some problems in interval estimation. J Royal Stat Soc B 1954; 16: 175-185.
14. Hsu A, Granneman GR, Witt G, et al. Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother 1997; 41: 898-905.
15. Perucca E. Clinical consequences of microsomal enzyme-induction by antiepileptic drugs. Pharmacol Ther 1978; 2: 285-314.
16. Guengerich FP. Oxidation of 17α-ethinylestradiol by human liver cytochrome P-450. Mol Pharmacol 1988; 33: 500-508.
17. Temellini A, Giuliani L, Pacifici GM. Interindividual variability in the glucuronidation and sulphation of ethinyloestradiol in human liver. Br J Clin Pharmacol 1991; 31: 661-664.
18. Orme ML, 'E, Back DJ, Ball S. Interindividual variation in the metabolism of ethynylestradiol. Pharmacol Ther 1989; 43: 251-260.
19. Quellet D, Hsu A, Granneman GR, et al. Assessment of the pharmacokinetic interaction between ntonavir (R) and clarithromycm (C). Clin Pharmacol Ther 1996; 59: 143.
20. Hsu A, Granneman GR, Sun E, et al. Assessment of single- and multiple-dose interactions between ntonavir and saquinavir [Abstract LB.B.6041]. XI International Conference on AIDS; 1996 July 7-12, Vancouver, BC, Canada.
21. Merry C, Barry MG, Mulcaby F, et al. Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients. AIDS 1997; 11: F29-F33.
22. Hsu A, Dennis S, Baroldi P, et al. Pharmacokinetic interaction between ritonavir and indinavir. Keystone Conference on AIDS Pathogenesis; 1997 April 8-13, Keystone, CO.
23. Kumar GN, Grabowski B, Lee R, Denissen JF. Hepatic drug metabolizing activities in rats after 14 days of oral administration of the HIV-1 protease inhibitor ntonavir (ABT-538). Drug Metab Disp 1996; 24: 615-617.
24. Cato A, Hsu A, Granneman R, et al. Assessment of the pharmacokinetic interaction between the HIV-1 protease inhibitor ABT-538 and zidovudine. [Abstract I34]. 35th ICAAC Annual Meeting; 1995 September 17-20, San Francisco, CA.
25. Hsu A, Granneman GR, Witt G, et al. Assessment of multiple doses of ritonavir on the pharmacokinetics of theophylline [Abstract Mo.B.1200]. XI International Conference on AIDS; 1996 July 7-12, Vancouver.
26. Back DJ, Breckenridge AM, Crawford FE, et al. The effect of rifampicin on the pharmacokinetics of ethinylestradiol in women. Contraception 1980; 21: 135-143.
27. Crawford P, Chadwick DJ, Martin C, Tjia J, Back DJ, Orme M. The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids. Br J Clin Pharmacol 1990; 30: 892-896.
28. Bolt HM, Kappus H, Bolt M. Effect of rifampicin treatment on the metabolism of oestradiol and 17α-ethinyloestradiol by human liver microsomes. Eur J Clin Pharmacol 1975; 8: 301-307.
29. Pacifi GM, Back DJ. Sulfation and glucuronidation of ethinyloestradiol in human liver in vitro. J Steroid Biochem 1988; 31: 345-349.